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In this work, we analyzed the role of the PI3K-p70 S6
kinase (S6K) signaling cascade in the stimulation of en-
dothelial cell proliferation. We found that inhibitors of
the p42/p44 MAPK pathway (PD98059) and the PI3K-p70
S6K pathway (wortmannin, Ly294002, and rapamycin)
all block thymidine incorporation stimulated by fetal
calf serum in the resting mouse endothelial cell line
1G11. The action of rapamycin can be generalized, since
it completely inhibits the mitogenic effect of fetal calf
serum in primary endothelial cell cultures (human um-
bilical vein endothelial cells) and another established
capillary endothelial cell line (LIBE cells). The inhibi-
tory effect of rapamycin is only observed when the in-
hibitor is added at the early stages of G0-G1 progression,
suggesting an inhibitory action early in G1. Rapamycin
completely inhibits growth factor stimulation of protein
synthesis, which perfectly correlates with the inhibition
of cell proliferation. In accordance with its inhibitory
action on protein synthesis, activation of cyclin D1 and
p21 proteins by growth factors is also blocked by prein-
cubation with rapamycin. Expression of a p70 S6K mu-
tant partially resistant to rapamycin reverses the inhib-
itory effect of the drug on DNA synthesis, indicating that
rapamycin action is via p70 S6K. Thus, in vascular en-
dothelial cells, activation of protein synthesis via p70
S6K is an essential step for cell cycle progression in
response to growth factors.
Blood vessels represent one of the most quiescent tissues of
adult mammals. However, in response to the appropriate stim-
uli, quiescent endothelium can produce new vessels in a proc-
ess known as angiogenesis (formation of new blood vessels from
pre-existing vasculature) (1). This happens in normal situa-
tions such as embryonic development and wound healing and
during the female reproductive cycle. However, activated blood
vessel growth is found in many diseases, such as tumor pro-
gression, diabetic retinopathy, and arthritis (2). In the last few
years, several studies have led to the discovery of inducers and
inhibitors of the angiogenic process. Fibroblast growth factors 1
and 2 (also known as aFGF and bFGF, respectively) and vas-
cular endothelial growth factor are among the inducers,
whereas thrombospondin-1, angiostatin, and endostatin are
inhibitors. However, the signaling mechanisms regulated by
these agents that control the reversible growth arrest state of
endothelial cells are not well understood.
Two signaling cascades have emerged as major players in the
mitogenic and anti-apoptotic response: the Ras-p42/p44
MAPK1 cascade and the PI3K-p70 S6 kinase (S6K) cascade.
Both pathways are initiated at the level of the plasma mem-
brane after activation of growth factor receptors and integrins.
The Ras-p42/p44 MAPK module implicates activation of the
low molecular weight GTP-binding protein p21ras and the se-
quential activation of a series of protein kinases: Raf-extracel-
lular signal-regulated kinase kinase-p42/p44 MAPK (3, 4). In
quiescent cells, p42/p44 MAPKs are cytoplasmic, but after
stimulation by growth factors, both isoforms translocate to the
nucleus, a key step in growth signaling (5). p42/p44 MAPKs
phosphorylate several transcription factors, such as members
of the Ets family, thereby controlling the expression of cell
cycle-regulated genes (6). Cyclin D1 is one of the multiple genes
that are positively controlled by the p42/p44 MAPK cascade (7),
and its induction is essential for the progression to S phase (8,
9).
Activation of PI3K by growth factors leads to the production
of 39-phosphorylated inositols that act as second messengers for
pleckstrin homology domain-containing signaling molecules,
such as Akt/PKB (10, 11). Activation of PI3K seems to be
required for cell growth but in a cell type- and stimulus-de-
pendent manner. Failure to activate p110 PI3K prevents reini-
tiation of DNA synthesis in response to platelet-derived growth
factor and epidermal growth factor in NIH3T3 cells (12, 13),
and the knockout of p85 PI3K results in a lack of B cell prolif-
eration in response to different agonists (14, 15). Expression of
a constitutively active PI3K favors DNA replication in 3T3-L1
adipocytes (16), and expression of an inducible form of PI3K is
sufficient for cell cycle entry in quiescent fibroblasts (17). Two
downstream signaling pathways have been described for PI3K,
Akt-GSK3 and p70/p85 S6K, which can be distinguished by
their sensitivity to the drug rapamycin (10, 11). p70/p85 S6K
are two isoforms of the kinase that controls the ribosomal
protein S6 phosphorylation in response to mitogens. They are
controlled by FRAP/mTOR, the target of rapamycin. p70/p85
S6K is activated by all mitogenic stimuli, including growth
factors, cytokines, and phorbol esters, and plays an essential
role in controlling the translation machinery (18, 19).
In this work, we analyzed the contribution of PI3K-p70/p85
S6K in the control of vascular endothelial cell growth. We have
found that inhibitors of the PI3K-p70/p85 S6K completely block
mitogenesis in these cells and that the mechanism implicates
the inhibition of protein synthesis.
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EXPERIMENTAL PROCEDURES
Materials—Ly294002 was obtained from Alexis, wortmannin and
rapamycin from BioMol, and PD98059 from New England Biolabs.
Cycloheximide was obtained from Sigma. Cell culture media, FCS,
glutamine, and antibiotics were obtained from Life Technologies, Inc.
The most commonly used chemicals were purchased from Sigma.
Cells and Culture Conditions—Murine lung endothelial 1G11 cells
were obtained from Drs. Alberto Mantovani and Annunciata Vecchi
(Instituto Ricerche Farmacologiche Mario Negri, Milan, Italy) (20).
They were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
containing 20% inactivated FCS, 50 units/ml penicillin, 50 mg/ml strep-
tomycin sulfate, 150 mg/ml endothelial cell growth supplement (Becton
Dickinson), 100 mg/ml heparin (Sigma), 1% nonessential amino acids,
and 2 mM sodium pyruvate. Before the incubation with growth factors,
cells were depleted for 24 h in a 1:1 mixture of DMEM and Ham’s F-12.
When indicated, rapamycin or the solvent ethanol was added 15 min
before the stimulation with 20% FCS.
Mouse brain capillary endothelial LIBE cells were obtained from Dr.
Claesson-Welsh (Ludwig Institute for Cancer Research, Uppsala, Swe-
den) and were cultivated as previously described (21). Human umbilical
vein endothelial cells (HUVEC) were obtained as described previously
(22) and were cultivated in EBM-2 supplemented endothelial cell me-
dium (Clonetics, BioWhittaker). The established Chinese hamster lung
fibroblast line CCL39 was cultivated in DMEM containing 7.5% FCS,
50 units/ml penicillin, and 50 mg/ml streptomycin sulfate.
Retroviral Infection and Generation of Wild Type and Rapamycin-
resistant p70 S6K-expressing 1G11 Cells—Retroviral supernatants
were generated by transient transfection of BOSC23 cells (23) with
plasmids pBabe, pBabe-p70 S6K (wild type), and pBabe-p70S6KE389-
D3E (rapamycin-resistant mutant) (24). Both constructions have an
amino-terminal Myc tag. Positive clones were selected on the basis of
resistance to puromycin (10 mg/ml) and confirmed by Western blot with
an antibody against Myc. The studies were performed using different
independent clones of 1G11-p70S6K WT and 1G11-p70S6KE389D3E
cells.
Determination of DNA Synthesis—1G11 cells were cultured in 24-
well plates for 48 h and deprived of growth factors for 24 h in a 1:1
mixture of DMEM and Ham’s F-12 medium. Cells were then stimulated
with fresh DMEM medium containing 20% FCS and 0.25 mCi/ml [meth-
yl-3H]thymidine (Amersham Pharmacia Biotech) (3 mM final concen-
tration). After 20 h of incubation, cells were fixed and washed twice
with ice-cold trichloroacetic acid (5%). The precipitated material was
solubilized with 0.1 N NaOH, and the incorporated radioactivity was
counted by liquid scintillation. When indicated, cells were incubated in
presence of thymidine for 24, 36, or 48 h before fixation. Results are
expressed as a percentage of the maximal [3H]thymidine incorporation
in the presence of FCS alone.
Determination of Protein Synthesis—1G11 cells were seeded in 12-
well plates and rendered quiescent by FCS starvation for 24 h. Cells
were rinsed with DMEM and [3H]leucine (L-leucine 2,3,4,5-3H-labeled),
2 mCi/ml, 0.8 mM final concentration) was added with or without 20%
FCS in 250 ml of DMEM. After 12 h of stimulation, cells were fixed and
washed twice with ice-cold trichloroacetic acid (5%). The precipitated
material was solubilized with 0.1 N NaOH, and the incorporated radio-
activity was counted by liquid scintillation. The lack of effect of the
rapamycin on leucine transport was measured by counting the radio-
activity in the first trichloroacetic acid wash.
Western Blot Analysis—Cells were washed twice with cold PBS and
lysed in Triton X-100 lysis buffer (50 mM Tris-HCl, pH 7.5, 100 mM
NaCl, 50 mM NaF, 5 mM EDTA, 40 mM b-glycerophosphate, 200 mM
sodium orthovanadate, 1024 M phenylmethylsulfonyl fluoride, 1 mg/ml
leupeptin, 1 mM pepstatin A, 4 mg/ml aprotinin, 1% Triton X-100) for 15
min at 4 °C. Insoluble material was removed by centrifugation at
12,000 3 g for 5 min at 4 °C. Proteins from cell lysates were separated
on acrylamide/bisacrylamide (29:1) SDS gels and electrophoretically
transferred to Immobilon-P membranes (Millipore Corp.) in 25 mM
Tris-HCl, 0.19 M glycine, 20% ethanol. Membranes were blocked in PBS
containing 5% nonfat dry milk for 1 h at 37 °C. The blots were then
incubated with polyclonal anti-p70 S6 kinase (Sigma); monoclonal anti-
p27 (Transduction Laboratories); monoclonal anti-cyclin D1 (NeoMar-
kers); polyclonal anti-p21 (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA); rabbit antiserum Alb-1, which specifically recognizes MAPK phos-
phatase 1 (MKP1) (25); polyclonal antiphospho-(Ser473)-Akt (New Eng-
land Biolabs); polyclonal anti-Akt (a generous gift from Dr. B. Hem-
mings, Friedrich Miescher Institut, Basel, Switzerland); monoclonal
9E10 anti-Myc (Roche Molecular Biochemicals); and monoclonal anti-
retinoblastoma protein (pRb) (Pharmigen) antibodies in the blocking
solution overnight at 4 °C. After washing in PBS, 0.1% Tween 20, blots
were incubated with horseradish peroxidase-conjugated goat anti-rab-
bit IgG (Promega) or anti-mouse IgG (Jackson Laboratories) in blocking
solution for 1 h and revealed with an ECL system (Amersham Phar-
macia Biotech).
Where indicated, the p70 S6 kinase and p42/p44 MAPK activities
were determined by a mobility shift assay in which, following cell lysis,
proteins were separated by SDS-polyacrylamide gel electrophoresis in a
9% gel (acrylamide:bisacrylamide 30:0.3 for p70 S6K) or 12.5% (acryl-
amide:bisacrylamide 30:0.2 for p42/p44 MAPKs), and Western blotting
was performed with anti-S6 kinase antiserum or anti-p42/p44 MAPK
antiserum EIB (26).
RESULTS
PI3K-p70 S6K and p42/p44 MAPK Inhibition Abolish DNA
Synthesis in 1G11 Endothelial Cells—In order to determine the
importance of PI3K activation in the stimulation of endothelial
cell proliferation by growth factors, quiescent 1G11 endothelial
cells were stimulated with 20% FCS in the absence or presence
of two different inhibitors of PI3K, wortmannin (27) and
Ly294002 (28), followed by measurement of DNA synthesis.
Thymidine incorporation was increased 50-fold in FCS-stimu-
lated cells. Preincubation with wortmannin or Ly294002
strongly inhibited FCS-stimulated thymidine incorporation
(Fig. 1A). Treatment with wortmannin or Ly294002 specifically
prevented PI3K activation, measured by the phosphorylation
state of two downstream targets of PI3K, Akt and p70 S6K
(Figs. 1B and 2B). These results indicate that activation of
PI3K is essential for G0/G1 to S phase progression of 1G11
vascular endothelial cells.
p70 S6K lies downstream of PI3K activation by growth fac-
tors (29, 30). Given the effect of PI3K inhibitors on DNA syn-
thesis in endothelial cells, next we studied the effect of rapa-
mycin (a specific inhibitor of p70 S6K activation by inhibition
of its activator FRAP/mTOR) on thymidine incorporation
stimulated by 20% FCS. In parallel, we evaluated the impor-
tance of p42/p44 MAPK activation by using an inhibitor of the
MAPK/extracellular signal-regulated kinase kinase 1 (MEK1),
PD98059. Preincubation with 50 mM PD98059 before stimula-
tion resulted in 80% inhibition of thymidine incorporation,
while preincubation with 10 nM rapamycin completely inhib-
ited the mitogenic effect of FCS (Fig. 2A). The same result was
obtained by measuring bromodeoxyuridine incorporation in the
presence of rapamycin (70% inhibition). Furthermore, the ad-
dition of rapamycin to exponentially proliferating 1G11 cells
diminished the total cell number by 65% after 4 days in the
presence of the drug (data not shown). The inhibition of p70
S6K activity was revealed by the lack of shift in a SDS-poly-
acrylamide gel (Fig. 2B) and by measuring phosphorylation of
a S6 peptide (data not shown). The specificity of this inhibition
is confirmed by the absence of p42/p44 MAPK inhibition in
response to rapamycin or Ly294002, while PD98059 only in-
hibited p42/p44 MAPK activation (Fig. 2B). These results
clearly indicate that PI3K-p70 S6K is essential for growth
factor mitogenicity in 1G11 endothelial cells. They also confirm
that, as seen in other cell systems, P70 S6K is a downstream
target of PI3K in vascular endothelial cells.
1G11 is a vascular endothelial cell line obtained from murine
lung. To investigate whether the effects of rapamycin are gen-
eral to vascular endothelial cells, we performed DNA synthesis
assays with primary cultures of HUVEC, and a different vas-
cular endothelial cell line, LIBE cells (a mouse brain capillary
cell line). Preincubation with rapamycin completely abrogated
FCS stimulation of thymidine incorporation in 1G11 and HU-
VEC cells and caused a 65% inhibition in LIBE cells (Fig. 3). In
contrast, preincubation of CCL39 fibroblasts in the presence of
rapamycin only slightly inhibited thymidine incorporation by
18%. These results suggest that the inhibitory effect of rapa-
mycin on mitogenicity is a general phenomenon for vascular
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endothelial cells.
Rapamycin Blocks 1G11 Endothelial Cells in the G1 Phase of
the Cell Cycle—It has been described that rapamycin abolishes
cell proliferation in T cells, whereas it only delays entry of
Swiss 3T3 fibroblasts into S phase (31). To address the tempo-
ral effect of rapamycin in 1G11 endothelial cells, thymidine
incorporation studies were performed for periods of time up to
48 h in the presence or in the absence of rapamycin. As is
shown in Fig. 4A, rapamycin blocked mitogenicity at all the
times assayed (96% of inhibition at 24 h, 87% at 36 h and 77%
at 48 h). This indicates that, in vascular endothelial cells,
rapamycin blocks cells in G1 phase rather than delaying entry
into the cell cycle.
To confirm that rapamycin affects a critical step during the
transition G0/G1 to S phase, a time course of rapamycin addi-
tion after serum stimulation was performed. As it has been
described, rapamycin addition before FCS completely blocked
thymidine incorporation (Fig. 4B). However, when rapamycin
was added after FCS stimulation, a gradual release of the
inhibition was observed during the prereplicative phase, re-
sulting in 50% inhibition at 6 h and only 22% when the cells
enter S phase (Fig. 4B). This result indicates that rapamycin
affects an early step in the G1 phase of the cell cycle and that
DNA replication is not sensitive to the inhibition by rapamycin.
This block in G1 was confirmed by the lack of hyperphospho-
rylation of pRb in cells pretreated with rapamycin and stimu-
lated for 18 h with FCS (data not shown).
Rapamycin Blocks Mitogenesis by Inhibiting Protein Synthe-
sis—The role of p70 S6K in the stimulation of the cellular
proliferation is based in its capacity to phosphorylate the ribo-
somal protein S6 in response to mitogens (18). This phospho-
rylation leads to an increase in the translation of a subset of
messenger RNAs, which are essential for the demands of pro-
liferating cells. Therefore, rapamycin could induce its effect on
endothelial cell proliferation by inhibiting growth factor-medi-
ated protein synthesis. To evaluate this possibility, we meas-
ured the variations in initial rates of protein synthesis. Serum
stimulation of quiescent 1G11 cells resulted in a 40% increase
in leucine incorporation (Fig. 5). Interestingly, the addition of
rapamycin completely blocked serum-stimulated protein syn-
FIG. 1. PI3K inhibition by wortmannin or Ly294002 prevents
serum-induced reinitiation of DNA synthesis in 1G11 cells. A,
quiescent 1G11 vascular endothelial cells were stimulated with 20%
FCS in the presence or the absence of the indicated concentrations of
wortmannin or Ly294002. After 20 h of incubation, DNA synthesis was
measured as described under “Experimental Procedures.” Results are
an average of four different experiments. B, quiescent 1G11 vascular
endothelial cells were stimulated with 20% FCS in the presence or the
absence of the indicated concentrations of wortmannin or Ly294002 for
1 h. After this time, cells were lysed, and Western blot was performed
using anti-active Akt (p-Akt) and total Akt (Akt) antibodies. The same
extracts were loaded on a 9% SDS-polyacrylamide gel (shift-up) and
blotted with anti-p70 S6K antibody. Hyperphosphorylated and active
forms of p70 S6K (indicated as pp70 S6K) migrated more slowly that
hypophosphorylated forms (indicated as p70 S6K). A representative
Western blot is shown.
FIG. 2. PD98059 and rapamycin inhibit serum-induced DNA
synthesis in 1G11 cells. A, 1G11 quiescent cells were preincubated for
15 min in the presence or in the absence of 50 mM PD98059, 15 mM
Ly294002, or 10 nM rapamycin, and DNA synthesis was measured as
described. Results are an average 6 S.E. of four independent experi-
ments. B, quiescent 1G11 vascular endothelial cells were stimulated
with 20% FCS for 1 h in the presence or absence of 50 mM PD98059, 15
mM Ly294002, or 10 nM rapamycin. Phospho-Akt, p70 S6K, or p42
MAPK was detected by immunoblotting with specific antibodies. Hy-
perphosphorylated and active forms of p42 MAPK (indicated as pp42
MAPK) and p70 S6K (indicated as pp70 S6K) migrated more slowly that
nonphosphorylated forms. These Western blots are representative of
three independent experiments.
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thesis, without having any effect on the basal synthesis rate.
We also assayed the effect of Ly294002 on protein synthesis.
Ly294002 potently inhibited protein synthesis and even re-
duced the basal levels by 30% (Fig. 5).
We next investigated whether the effect of rapamycin on
thymidine incorporation correlated with protein synthesis in-
hibition. 1G11 cells were preincubated in the presence of dif-
ferent concentrations of rapamycin (from 0.01 to 10 nM) fol-
lowed by measurement of p70 S6K activation and the rates of
thymidine and leucine incorporation. As observed in Fig. 6A,
rapamycin inhibited thymidine incorporation stimulated by
FCS with the same dose-dependence than protein synthesis. In
both cases, the IC50 for rapamycin is approximately 0.1 nM with
a total inhibition at 1 nM. These effects correlated perfectly
with the inhibition of p70 S6K activity as measured by the
shift-up assay (Fig. 6B). This strict dependence between the
rate of DNA synthesis and the rate of protein synthesis was
confirmed with the use of a potent inhibitor of protein synthe-
sis, cycloheximide. As is observed in Fig. 6C, cycloheximide
inhibited leucine and thymidine incorporation with a similar
IC50 (0.015 mg/ml) for both processes. These results therefore
suggest that the block of mitogenesis induced by rapamycin is
due to the inhibition of serum-stimulated protein synthesis.
In order to confirm the role of p70 S6K on the stimulation of
protein synthesis by growth factors, we analyzed the effect of
rapamycin on the synthesis of two proteins expressed in the G1
phase, cyclin D1 and p21. Treatment of quiescent cells with
20% FCS caused an induction of cyclin D1 for up to 16 h, with
a maximum at 12 h (Fig. 7). This increase was completely
abrogated by treatment with 10 nM rapamycin. The same result
was obtained with the induction of p21, a growth factor-in-
duced inhibitor of the cyclin-dependent kinases (32) (Fig. 7).
We also analyzed the effect of rapamycin on the growth factor-
mediated degradation of the cyclin-dependent kinase inhibitor
p27. As is observed in Fig. 7, the decrease in p27 levels was not
affected by treatment with rapamycin.
Cyclin D1 and p21 are induced after long term stimulation,
with the maximal expression attained around 12 h. In contrast,
MAPK phosphatase 1 is induced by growth factors much ear-
lier than cyclin D1 or p21, with a maximum at 1 h that is
maintained until 4 h and thereafter returned to basal levels
after 12 h (Fig. 8A). Interestingly, rapamycin had no effect on
the induction of MAPK phosphatase 1, despite the fact that the
drug immediately affected protein synthesis (Fig. 8B). Thus,
the lack of effect of rapamycin on MAPK phosphatase 1 reflects
the selective action of p70 S6K on the translation of different
cell cycle-regulated proteins.
Overexpression of a p70 S6K Mutant That Is Resistant to
Rapamycin Decreases Rapamycin Sensitivity of 1G11 Cells—
The target of rapamycin is FRAP/mTOR, a kinase that regu-
lates p70 S6K. Moreover, FRAP/mTOR also has a direct effect
on the initiation of protein synthesis by phosphorylating and
inactivating eIF4E-BP1/PHAS-1, a repressor of mRNA trans-
lation (33–35). To evaluate whether the effects of rapamycin
are driven by p70 S6K inhibition, we isolated 1G11 cells stably
expressing either wild type or a rapamycin-resistant mutant
form of p70 S6K (p70S6K-E389D3E) (24). Different clones over-
expressing the wild type form or the p70S6K-E389D3E form
(Fig. 9A) were analyzed for their capacity to reinitiate DNA
synthesis in the presence of different concentrations of rapa-
mycin. Rapamycin inhibited thymidine incorporation in clones
overexpressing the wild type form with exactly the same dose
response as in parental cells (Fig. 9B). In contrast, cells over-
expressing the rapamycin-resistant form of p70 S6K presented
a clear resistance to the inhibition by the drug. The dose-
response curves were shifted 1 log rightward for the clones
expressing the rapamycin-resistant p70 S6K variant. This re-
FIG. 3. Rapamycin inhibits DNA synthesis in different vascu-
lar endothelial cell types but not in CCL39 fibroblasts. 1G11
mouse lung vascular endothelial cells, LIBE mouse brain capillary
vascular endothelial cells, primary HUVEC, and CCL39 fibroblasts
were depleted of growth factors for 24 h. After this time, cells were
stimulated with 20% FCS for 20 h in the presence or absence of 10 nM
rapamycin, and DNA synthesis was measured as described. Results are
an average of two (CCL39 cells) or five experiments (rest of cells).
FIG. 4. The inhibitory action of rapamycin is persistent and
affects early in the G1 phase. A, quiescent 1G11 vascular endothelial
cells were stimulated with 20% FCS in presence of [methyl-3H]thymi-
dine for 24, 36, and 48 h with or without rapamycin. Cells were then
processed as described. Results are an average 6 S.E. of three different
experiments. B, quiescent 1G11 cells were restimulated with 20% FCS.
10 nM rapamycin was added at time 0 or 1, 2, 4, 8, or 12 h after the
addition of FCS. After 20 h of total incubation, DNA synthesis was
measured. Results are an average 6 S.E. of three independent
experiments.
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sult indicated that the effect of rapamycin is p70 S6K-depend-
ent and is not caused by a direct effect of FRAP/mTOR kinase
on protein synthesis or other possible side effects of rapamycin.
DISCUSSION
In this work we have shown that inhibition of p42/p44 MAPK
and PI3K-p70 S6K cascades blocks fetal calf serum-induced
DNA synthesis reinitiation in vascular endothelial cells. The
arrest of proliferation by inhibition of the p42/p44 MAPK path-
way is not surprising, knowing the central role played by this
cascade in the stimulation of cell proliferation (4). In endothe-
lial cells, it has been described that PD98059 completely inhib-
its thymidine incorporation stimulated by vascular endothelial
growth factor (36–38) and affects the mitogenic effect of bFGF
(39). Moreover, repression of p42/p44 MAPK activity in conflu-
ent endothelial cells is required for the maintenance of the
quiescent state (21). In contrast, much less is known about the
role of the PI3K-Akt-p70 S6K module in the control of endo-
thelial cell growth. Our results have shown that two different
inhibitors of PI3K, wortmannin and Ly294002, completely
block serum-stimulated DNA synthesis in vascular endothelial
cells. These inhibitors prevent p70 S6K activation, confirming
that PI3K activity is required for activation of p70 S6K but not
p42/p44 MAPK. Inhibition of PI3K results in a block of endo-
thelial cell proliferation that correlates with the inhibition of
p70 S6K (compare inhibition of thymidine incorporation in
wortmannin-treated cells with that of Akt and p70 S6K). How-
ever, more interestingly, specific inhibition of p70 S6K activa-
tion by rapamycin was found to be sufficient to inhibit DNA
synthesis reinitiation. Moreover, only p70 S6K activation and
not Akt phosphorylation was found to be sensitive to rapamy-
cin treatment. This result points out that, although Akt acti-
vation could have a key role in cell survival on its own, Akt
stimulation is not sufficient to trigger DNA replication. This
finding, which highlights the key role of p70 S6K in vascular
endothelial cell proliferation, was already clearly established
for lymphocytes, although the conclusions were more loose in
other systems such as fibroblasts. Indeed, when p70 S6K is
fully inhibited by rapamycin in CCL39 fibroblasts (Fig. 3 and
data not shown), DNA synthesis reinitiation is only minimally
affected without effects on protein synthesis. The cause for this
difference between fibroblasts and vascular endothelial cells is
still unclear.
Activation of the protein synthesis by growth factors is an
essential step for cell cycle progression, and its inhibition
causes fibroblast growth arrest in G0/G1 (40, 41). PI3K-p70 S6K
is one of the most important signaling pathways implicated in
the stimulation of protein synthesis. Thus, p70 S6K is respon-
sible for the phosphorylation of the ribosomal 40 S subunit S6
protein. When phosphorylated, polysomes will specifically
translate a subset of mRNAs, all characterized by an oligopy-
rimidine tract at their 59-untranslated region. These mRNAs
are coding for members of the protein synthetic machinery (18,
41–43). Since the IC50 for rapamycin was identical for the
inhibition of serum-induced DNA synthesis and protein syn-
thesis, the inhibition of protein synthesis by rapamycin is likely
to be responsible for the block of DNA synthesis in vascular
endothelial cells. It is interesting to note that rapamycin only
affects the increase in leucine incorporation induced by growth
factors without affecting the basal rate of protein synthesis.
Thus, it is possible that rapamycin would only affect the ex-
pression of growth factor-controlled gene products. Accord-
ingly, we have found that rapamycin completely prevents the
FIG. 5. Rapamycin inhibits serum-stimulated protein synthe-
sis. Quiescent 1G11 endothelial cells were stimulated or not (Basal) for
12 h with 20% FCS in the presence of [3H]leucine and either no inhib-
itor, 15 mM Ly294002, or 10 nM rapamycin. Protein synthesis was
measured as described under “Experimental Procedures.” Results are
expressed as a percentage of the maximal [3H]leucine incorporation in
the presence of FCS alone and are an average 6 S.E. of four different
experiments.
FIG. 6. Inhibition of DNA synthesis by rapamycin correlates
with the inhibition of protein synthesis. A, quiescent 1G11 vascu-
lar endothelial cells were stimulated with 20% FCS in presence of the
indicated concentrations of rapamycin. Thymidine or leucine incorpo-
ration was measured as described. Results are an average of two dif-
ferent experiments and are expressed as a percentage of the maximal
incorporation obtained in presence of FCS alone. B, quiescent 1G11
cells were stimulated with 20% FCS for 1 h in the presence of the
indicated concentrations of rapamycin. Cells were lysed, and p70 S6K
was immunodetected with a specific antibody. The active hyperphos-
phorylated forms are indicated (pp70 S6K). C, quiescent 1G11 endothe-
lial cells were stimulated with 20% FCS in presence of the concentra-
tions of cycloheximide indicated. Thymidine or leucine incorporation
were measured as described before. Results are expressed as a percent-
age of the maximal [3H]thymidine or leucine incorporation in the pres-
ence of FCS alone and are an average of two different experiments.
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synthesis of one of the essential members of the Cdk-cyclin
complexes of the G1 phase, cyclin D1, precluding the phospho-
rylation of Rb product and therefore the entry into S phase.
Moreover, it is interesting to note that treatment with rapa-
mycin discriminates between growth factor-regulated gene
products, inhibiting cyclin D1 and p21 synthesis but not the
expression of MAPK phosphatase 1, an early gene product.
These results can be explained by the presence of an oligopy-
rimidine tract in the 59-untranslated region of the cyclin D1
mRNA. However, other mRNA determinants could be involved,
since about 30% of newly synthesized proteins are inhibited by
rapamycin (19, 44). Rapamycin’s target is the immunophilin
FK506-binding protein, which binds to the kinase FRAP/
mTOR. FRAP/mTOR is a major upstream component of the
p70/p85 S6K activation and plays a direct role in the stimula-
tion of protein synthesis. Thus, by phosphorylation FRAP/
mTOR inactivates the translation inhibitor eIF4E BP1/
PHAS-1 (33–35). Although we cannot discard the possibility of
a direct effect of FRAP/mTOR on protein synthesis and prolif-
eration of endothelial cells, we demonstrate in this study that
overexpression of a rapamycin-resistant form of p70 S6K par-
tially overcomes the effect of rapamycin. This result reinforces
the notion that activation of p70 S6K by itself is an important
step for endothelial cell cycle progression. Finally, we cannot
exclude other effects of the stimulation of p70 S6K important
for the mitogenic cascade in endothelial cells, but it seems that
this is not due to the persistence of high levels of the Cdk-cyclin
inhibitor p27 after growth factor stimulation. The role of p27 in
the anti-proliferative effect of rapamycin is controversial (32,
45–47). In endothelial 1G11 cells, we have not found any effect
of rapamycin on p27 regulation. It is plausible that, due to the
decrease in cyclin D1 levels, the residual amounts of p27 are
sufficient to explain the cell cycle arrest in presence of
rapamycin.
In conclusion, at least two pharmacologically separate
growth-signaling cascades are operating in vascular endothe-
lial cells. These cascades lead to activation of critical protein
FIG. 7. Rapamycin blocks cyclin D1 and p21 induction without
effect on p27 degradation. Quiescent 1G11 vascular endothelial cells
were stimulated with 20% FCS in the presence or absence of 10 nM
rapamycin. After the times indicated, cells were lysed, and Western
blots were performed with anti-cyclin D1, anti-p21, and anti-p27 anti-
bodies. A representative Western blot is shown.
FIG. 8. Rapamycin does not block synthesis of an early gene
protein, MAPK phosphatase 1 (MKP1). A, quiescent 1G11 vascular
endothelial cells were stimulated with 20% FCS for the indicated peri-
ods of time in the presence or the absence of 10 nM rapamycin. Cells
were lysed, and Western blot analysis was performed with anti-MAPK
phosphatase 1 and anti-cyclin D1 antibodies. A representative Western
blot is shown. B, quiescent 1G11 cells were stimulated or not (Basal)
with 20% FCS in the presence or the absence of 10 nM rapamycin and
with [3H]leucine. At the times indicated, leucine incorporation was
measured as described. A representative experiment is shown.
FIG. 9. Overexpression of a p70 S6K rapamycin-resistant form
(p70 S6KE389D3E) attenuates inhibition of DNA synthesis by
rapamycin. A, 1G11 parental cells or overexpressing 1G11-p70
S6KE389D3E cells (two different cell clones, 21 and 26) were lysed, and
overexpression of p70 S6KE389D3E-Myc was immunodetected with a
monoclonal antibody against Myc. A representative Western blot is
shown. B, quiescent parental 1G11 cells or different clones overexpress-
ing wild type p70 S6K (p70 S6KWT) or p70 S6KE389D3E (clones ED3E
21 and 26) were stimulated with 20% FCS in presence of the indicated
concentrations of rapamycin and DNA synthesis measured. Results are
expressed as a percentage of maximal incorporation in presence of FCS
alone for each cell clone. A representative experiment is shown.
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kinases that cooperate at the level of gene induction (p42/p44
MAPK) and protein synthesis (p70 S6K). The extreme sensi-
tivity of vascular endothelial cells to immunosuppressive drugs
such as rapamycin as shown here could have great potential in
therapeutic intervention.
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